苑东生物：注射用YLSH003启动I/II期临床试验并完成首例入组

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shanghai Youlu, has initiated clinical trials for a new biopharmaceutical, YLSH003, targeting advanced solid tumors, with the first patient successfully enrolled for treatment [1] Group 1: Product Development - YLSH003 is a novel antibody-drug conjugate targeting tissue factor, and the company has submitted an international patent application for the related technology [1] - The clinical trials consist of Phase I and Phase II studies, with Phase I focusing on safety and tolerability, while Phase II will assess efficacy [1] - The drug is expected to be accepted and approved by 2025, with the first patient already enrolled in Phase I and recruitment for additional subjects ongoing [1] Group 2: Market Context - The pharmaceutical development process is characterized by high risks, and the timeline for project approval and outcomes remains uncertain [1]